Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Sergio Cifuentes, Medical Oncologist – Breast Cancer and Gastrointestinal Tumor Units at Las Américas Clinic AUNA – Oncology Institute, shared on X:
“MARIOPPSA
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC.”
Read Further: Giannis Mountzios: FLAURA2 vs. MARIPOSA at WCLC25
Title: Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Authors: James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Antonio Passaro, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, Michael Thomas, Danny Nguyen, Sai-Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, Manolo D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Ali Nahit Şendur, Ozan Yazici, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Sang-We Kim, Shirish M. Gadgeel, Scott Owen, John Xie, Tao Sun, Jaydeep Mehta, Raja Venkatasubramanian, Mariah Ennis, Elizabeth Fennema, Mahesh Daksh, Amy Roshak, Julie Man, Roland E. Knoblauch, Joshua M. Bauml, Mahadi Baig, Sujay Shah, Seema Sethi, Byoung Chul Cho
Read The Full Article at NEJM.
Read Further: Amivantamab–Lazertinib Improves Survival Over Osimertinib in EGFR-Mutated NSCLC
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023